Tamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathways
- 29 August 2013
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 454 (3), 467-477
- https://doi.org/10.1042/bj20130580
Abstract
Macrophage adipocyte fatty acid-binding protein (FABP4) plays an important role in foam cell formation and development of atherosclerosis. Tamoxifen inhibits this disease process. In the present study, we determined whether the anti-atherogenic property of tamoxifen was related to its inhibition of macrophage FABP4 expression. We initially observed that tamoxifen inhibited macrophage/foam cell formation, but the inhibition was attenuated when FABP4 expression was selectively inhibited by siRNA. We then observed that tamoxifen and 4-hydroxytamoxifen inhibited FABP4 protein expression in primary macrophages isolated from both the male and female wild-type mice, suggesting that the inhibition is sex-independent. Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARγ (peroxisome-proliferator-activated receptor γ). Associated with the decreased protein expression, Fabp4 mRNA expression and promoter activity were also inhibited by tamoxifen and 4-hydroxytamoxifen, indicating transcriptional regulation. Analysis of promoter activity and EMSA/ChIP assays indicated that tamoxifen and 4-hydroxytamoxifen activated the nGRE (negative glucocorticoid regulatory element), but inhibited the PPRE (PPARγ regulatory element) in the Fabp4 gene. In vivo, administration of tamoxifen to ApoE (apolipoprotein E)-deficient (apoE−/−) mice on a high-fat diet decreased FABP4 expression in macrophages and adipose tissues as well as circulating FABP4 levels. Tamoxifen also inhibited FABP4 protein expression by human blood monocyte-derived macrophages. Taken together, the results of the present study show that tamoxifen inhibited FABP4 expression through the combined effects of GR and PPARγ signalling pathways. Our findings suggest that the inhibition of macrophage FABP4 expression can be attributed to the anti-atherogenic properties of tamoxifen.Keywords
This publication has 41 references indexed in Scilit:
- Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Estrogen Signaling and Cardiovascular DiseaseCirculation Research, 2011
- Deficiency of PXR decreases atherosclerosis in apoE-deficient miceJournal of Lipid Research, 2011
- Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular eventsEuropean Heart Journal, 2010
- The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphismJournal of Applied Genetics, 2006
- Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal womenAmerican Heart Journal, 2004
- Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophagesBiochemical and Biophysical Research Communications, 2004
- Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell lineJournal of Lipid Research, 2003
- PPARγ Activation Induces the Expression of the Adipocyte Fatty Acid Binding Protein Gene in Human MonocytesBiochemical and Biophysical Research Communications, 1999
- Tamoxifen Inhibits Arterial Accumulation of LDL Degradation Products and Progression of Coronary Artery Atherosclerosis in MonkeysArteriosclerosis, Thrombosis, and Vascular Biology, 1997